Evidence map›Paper›PMID 35552767›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2022

Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice.

Manuel Guhlich, Teresa Esther Maag, Leif Hendrik Dröge, Rami A El Shafie, Andrea Hille, Sandra Donath, Markus Anton Schirmer, Olga Knaus, Friedemann Nauck, Tobias Raphael Overbeck and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. BMC cancer · 2026
    Article
  3. Review
  4. Emergency radiation therapy in modern-day practice: Now or never, or never again ?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Manuel GuhlichClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany. manuel.guhlich@med.uni-goettingen.de.ORCID 0000-0002-2599-6196
Teresa Esther MaagClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Leif Hendrik DrögeClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Rami A El ShafieClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Andrea HilleClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Sandra DonathClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Markus Anton SchirmerClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Olga KnausClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Friedemann NauckDepartment of Palliative Medicine, University Medical Center Göttingen, Göttingen, Germany.
Tobias Raphael OverbeckDepartment of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Marc HinterthanerLung Cancer Center, Medical University Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), Göttingen, Germany.
Wolfgang KörberLung Cancer Center, Medical University Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), Göttingen, Germany.
Stefan AndreasLung Cancer Center, Medical University Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), Göttingen, Germany.
Achim RittmeyerLung Cancer Center, Medical University Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), Göttingen, Germany.
Martin LeuClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Stefan RiekenClinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Universitätsmedizin Göttingen · DEEvangelisches Krankenhaus Göttingen-Weende · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSuperior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive disease. Despite several publications, recent data concerning symptom relief and oncological outcome as well as potential confounders in treatment response are still scarce.

methodsWe performed a retrospective single-center analysis of patients receiving urgent RT between 2000 and 2021 at the University Medical Center Göttingen. Symptom relief was evaluated by CTCAE score during the RT course. Effects of variables on symptom relief were assessed by logistic regression. The impact of parameters on overall survival (OS) was evaluated using Kaplan-Meier plot along with the log-rank test and by Cox regression analyses. Statistically significant (p-value < 0.05) confounders were tested in multivariable analyses.

resultsA total of 79 patients were included. Symptom relief was achieved in 68.4%. Mean OS was 59 days, 7.6% (n = 6) of patients showed long-term survival (> 2 years). Applied RT dose > 39 Gy, clinical target volume (CTV) size < 387 ml, concomitant chemotherapy, and completion of the prescribed RT course were found to be statistically significant for OS; applied RT dose and completion of the prescribed RT course were found to be statistically significant for symptom relief.

conclusionSymptom relief by urgent RT for SVCS was achieved in the majority of patients. RT dose and completion of the RT course were documented as predictors for OS and symptom relief, CTV < 387 ml and concomitant chemotherapy were predictive for OS.

Indexed as

NeoplasmsSuperior Vena Cava SyndromeHumansPrognosisRetrospective StudiesTreatment OutcomeRadiotherapyRetrospectiveSuperior Vena Cava SyndromeSymptom relief

Identifiers

PMID35552767
PMCPMC9700593
OpenAlexW4280558311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.